The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease - Wikidata - wikimedia - TriplyDB

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

http://www.wikidata.org/entity/Q28005463

about

Checkpoints to the Brain: Directing Myeloid Cell Migration to the Central Nervous System Towards Personalized Intervention for Alzheimer's Disease Immune Regulation of Antibody Access to Neuronal Tissues Bridging Type 2 Diabetes and Alzheimer's Disease: Assembling the Puzzle Pieces in the Quest for the Molecules With Therapeutic and Preventive Potential The Arc Gene Confers Genetic Susceptibility to Alzheimer's Disease in Han Chinese.The impact of fraudulent and irreproducible data to the translational research crisis - solutions and implementation.Future Directions in Imaging Neurodegeneration.Recent Progress in Alzheimer's Disease Research, Part 3: Diagnosis and Treatment.Aromatherapy and Aromatic Plants for the Treatment of Behavioural and Psychological Symptoms of Dementia in Patients with Alzheimer's Disease: Clinical Evidence and Possible Mechanisms.Neuropsychological Testing and Machine Learning Distinguish Alzheimer's Disease from Other Causes for Cognitive Impairment.Evaluation of a DNA Aβ42 vaccine in adult rhesus monkeys (Macaca mulatta): antibody kinetics and immune profile after intradermal immunization with full-length DNA Aβ42 trimer.Old Maids: Aging and Its Impact on Microglia Function.An intranasally delivered peptide drug ameliorates cognitive decline in Alzheimer transgenic mice.Amyloid positron emission tomography in sporadic cerebral amyloid angiopathy: A systematic critical update Pharmacological and Toxicological Properties of the Potent Oral γ-Secretase Modulator BPN-15606.A vaccine with Aβ oligomer-specific mimotope attenuates cognitive deficits and brain pathologies in transgenic mice with Alzheimer's disease Phage display and kinetic selection of antibodies that specifically inhibit amyloid self-replication.Drug candidates in clinical trials for Alzheimer's disease.Young microglia restore amyloid plaque clearance of aged microglia.Significant Improvement in Cognition in Mild to Moderately Severe Dementia Cases Treated with Transcranial Plus Intranasal Photobiomodulation: Case Series Report.Integrated analysis of genetic, behavioral, and biochemical data implicates neural stem cell-induced changes in immunity, neurotransmission and mitochondrial function in Dementia with Lewy Body mice.A novel pathway for amyloids self-assembly in aggregates at nanomolar concentration mediated by the interaction with surfaces.Biotic/Abiotic Stress-Driven Alzheimer's Disease.Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice.Atomic structures of fibrillar segments of hIAPP suggest tightly mated β-sheets are important for cytotoxicity.Apolipoprotein E metabolism and functions in brain and its role in Alzheimer's disease Large Soluble Oligomers of Amyloid β-Protein from Alzheimer Brain Are Far Less Neuroactive Than the Smaller Oligomers to Which They Dissociate.Association between Aβ and tau accumulations and their influence on clinical features in aging and Alzheimer's disease spectrum brains: A [11C]PBB3-PET study Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of Aβ42 and Aβ40 peptides by γ-secretase.APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice.In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer's Disease.HuCNS-SC Human NSCs Fail to Differentiate, Form Ectopic Clusters, and Provide No Cognitive Benefits in a Transgenic Model of Alzheimer's Disease.Amyloid-beta immunotherapy: the hope for Alzheimer disease?Subcortical Shape Changes, Hippocampal Atrophy and Cortical Thinning in Future Alzheimer's Disease Patients.Dissociable diffusion MRI patterns of white matter microstructure and connectivity in Alzheimer's disease spectrum.Alzheimer's Toxic Amyloid Beta Oligomers: Unwelcome Visitors to the Na/K ATPase alpha3 Docking Station.New drugs in psychiatry: focus on new pharmacological targets.Alzheimer's disease in people with Down's syndrome: the prospects for and the challenges of developing preventative treatments Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome.Neuropathology of White Matter Lesions, Blood-Brain Barrier Dysfunction, and Dementia.

P2860

Q28066906-41F4484D-7F02-49B5-99FC-27E33C5D5AE1 Q28080098-100667A5-1500-48F5-B907-30C272C1AA5D Q28733365-B5D83CD2-B6E2-4252-AF9F-A972FF64401B Q29994589-4A3E3DC1-FC38-4375-8A8C-759AC2599AC3 Q30397753-CF1EBB00-B554-4904-B048-B106EBFAD1FA Q31140087-D4D68E5D-603F-4C23-B4E4-28C999D6B4B9 Q31162702-7574CAFA-1FCB-47D4-ACDD-99B329B1C4E1 Q33556068-33154C09-863F-489A-B087-9DF6E9BAE3F1 Q33561116-579F44F6-20F2-4097-A780-9A60CEF9FF94 Q33599831-0C8965AF-4AA3-4E2C-B8F0-1F0957FBB47F Q33604583-E787BFA5-2C7B-4470-88BB-C60F65D29760 Q33624540-25253025-E422-4D80-B231-EA26B283C6A0 Q33626081-26008C9A-810A-474B-806A-402918C3866A Q33700069-8CBB231A-9BB6-4F24-BF3D-84D2182D80F0 Q33754484-569639B2-D921-4524-B27B-639A42E0CD5B Q33771800-BEDE9C52-D81A-482A-ABFF-D8F59880D2CD Q33847755-2B5D8C1B-E75E-4D1C-8677-4F17A8CEE545 Q33916749-7EFD04E9-D24B-48BD-A291-65237934F9CF Q36231976-6750671D-0E32-4468-9BAC-A7C74B16F37C Q36276846-11B0FB4C-2873-42F8-B063-32ADCE68389F Q36304737-A75D186E-D8E9-4642-B449-9B08D2DCE014 Q36327854-18F7D78B-A3A9-4BEA-8FA5-CD06D5CF287D Q37430445-BEBA20F3-5815-45CE-9377-DE8D7DFACA15 Q37504954-F6D52E7F-E3BA-4D92-9800-F2ED8DC6AE2D Q37552594-25251472-E88F-4A30-BA91-0E8AA8A57FF1 Q37557940-98EAA8E7-6CD1-4FBE-BEE7-B0743E49FA03 Q37558841-8A7C4E6F-9D3A-47E9-B8A0-695B14394A85 Q37600680-5A082D3D-D6B1-4418-88D6-FB87CA324009 Q37612568-9E205720-7729-4875-BAA0-77AB39755719 Q37615879-E97A3184-F744-44C7-8140-C053E2396EC5 Q37622090-A707DA5E-6DF4-4F55-A200-E0484EA20270 Q37644720-D5649154-CB76-4D7C-8506-5ED6184C96F1 Q37679265-EF08A2C9-E731-40E8-B20F-7315A9F2F8AB Q37683684-3F0533BF-40E7-4F0C-B9FF-5C7E1984129A Q37719499-C852903A-4CD3-4C58-BEDB-3BE0BEE6D243 Q37724402-BDA906AC-480F-4E16-8D42-3FDCD986805A Q37730207-1FA2C3B6-1140-48B8-B710-ADF4D4EDC1D6 Q37730984-B40FA760-E00F-4F28-A23F-986CCE843F9E Q37741452-5E69D85A-4728-43D5-A346-40E13F6DE155 Q38601654-77E0DFAE-03A5-4FB6-9055-412189A3C8A4

P2860

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

http://www.wikidata.org/entity/Q28005463

description

2016 nî lūn-bûn

@nan

2016 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

@ast

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

@en

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

@nl

type

label

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

@ast

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

@en

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

@nl

prefLabel

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

@ast

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

@en

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

@nl

P1433

Q28005463-DC05A0BD-5064-4789-84C1-6131255188EE

P1476

Q28005463-A8346F33-75FC-4600-A64D-609DD997240E

P2093

Q28005463-03CA1E53-1E13-46A4-BE6A-EC30635DF5A4

Q28005463-12E40B52-77E5-4262-B4F9-0CA4B1D709E6

Q28005463-1E6C900B-C00A-4B56-9C0C-80060710731D

Q28005463-222BDC24-7AF3-451A-BBC1-6B6ABDD8BCDD

Q28005463-253AB8CF-3D7B-456F-8A60-0D191B7662FC

Q28005463-274A1E29-1F2D-471C-869E-2D08C580CD1A

Q28005463-2BD38514-C88A-4374-B71D-709C6618DB93

Q28005463-2E131F47-D64A-4192-8EF7-BE95E21B9ADB

Q28005463-4F2988A6-7AE2-4982-A09C-5787CB137CDC

Q28005463-5FEC373B-8308-4BF2-84EC-DB6EFC6CF37F

P2860

Q28005463-033B35FF-C848-4A1D-BE01-0830B167EDC1

Q28005463-06B0DEBD-0717-4691-85C7-F3773C149BD8

Q28005463-14B622CF-5BA9-4FAD-8C24-5F38008BB0F0

Q28005463-15BA8C1A-1F86-49F2-93A4-DB8849DD89B3

Q28005463-16379FB4-B73F-4928-9EF3-294548BFA7E7

Q28005463-17D79AD9-64A4-4EDC-839F-7EFCCFD875B0

Q28005463-2032CFDD-469E-413B-AA5E-DCA85F0E7254

Q28005463-27CE6D3C-6671-4DCD-BB60-730EE2EDA948

Q28005463-2CEF7F95-8ADC-44C2-9C03-41C40BD034CF

Q28005463-33D820F9-D24B-4F65-818D-582E5C518C06

P2888

Q28005463-AF08DEE1-EE01-41A0-B836-CAFD60BF31B6

P304

Q28005463-2A0967CE-4857-49C8-B07E-F70DF45DD11B

P31

Q28005463-844D2168-81CF-4BFF-BCE2-944B81AF29FC

P3181

Q28005463-C66E1BA9-F45F-46DD-8749-7F5D8FEC6EC2

P356

Q28005463-E0E0B216-48B0-4450-A33F-00C5E2EDDC1C

P407

Q28005463-941DB577-7254-4CCB-8218-B8CE47FDD9AA

P433

Q28005463-BEFAE265-F5C5-425A-9AF7-D5A5BEE4CBC1

P478

Q28005463-FD7A9C83-FF6F-4336-AA9F-977ADCAC3252

P50

Q28005463-2D83A0A9-4325-43E4-9E49-DE2FFED20F06

Q28005463-83D2F9C1-2AC9-41C4-8B0E-0BAC2EEBEDFB

P577

Q28005463-29DCD07B-EE24-48E8-81C5-732EDD5A5126

P6179

Q28005463-B0FA77C0-863A-42D9-817F-2CF0050C580D

P698

Q28005463-82331ADF-70F3-449C-AB54-E36019ECD82A

P921

Q28005463-10607D00-2768-4C46-8251-C796D9BFEE5C

Q28005463-B459212E-13C3-4C91-B2FF-890F3B116FEB

P3181

P356

P1433

P1476

The antibody aducanumab reduces Aβ plaques in Alzheimer's disease

@en

P2093

Alfred Sandrock

http://www.w3.org/2001/XMLSchema#string

Alvydas Mikulskis

http://www.w3.org/2001/XMLSchema#string

Christoph Hock

http://www.w3.org/2001/XMLSchema#string

Fang Qian

http://www.w3.org/2001/XMLSchema#string

H Moore Arnold

http://www.w3.org/2001/XMLSchema#string

James Ferrero

http://www.w3.org/2001/XMLSchema#string

Jan Grimm

http://www.w3.org/2001/XMLSchema#string

Jeff Sevigny

http://www.w3.org/2001/XMLSchema#string

John O'Gorman

http://www.w3.org/2001/XMLSchema#string

Kenneth Rhodes

http://www.w3.org/2001/XMLSchema#string

P2860

Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer aβ oligomer bound to cellular prion protein

Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

Amyloid-β Receptors: The Good, the Bad, and the Prion Protein

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide

Alzheimer's disease: the amyloid cascade hypothesis

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques

Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy

Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis.

P2888

P304

50-56

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3313614

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NATURE19323

http://www.w3.org/2001/XMLSchema#string

P407

P433

7618

http://www.w3.org/2001/XMLSchema#string

P478

537

http://www.w3.org/2001/XMLSchema#string

P50

Robert Scannevin

Paul H. Weinreb

P577

2016-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1029992555

http://www.w3.org/2001/XMLSchema#string

P698

27582220

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease